L1920
LY255283
≥98% (HPLC), powder
别名:
1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19H28N4O3
化学文摘社编号:
分子量:
360.45
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
off-white to light yellow
solubility
DMSO: >20 mg/mL
originator
Eli Lilly
storage temp.
−20°C
SMILES string
CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2
InChI
1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
InChI key
WCGXJPFHTHQNJL-UHFFFAOYSA-N
Application
LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils. LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.
Biochem/physiol Actions
LY255283 is a competitive leukotriene B4 receptor antagonist, specific to the BLT2 receptor subtype.
LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC50 values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.
Features and Benefits
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
D G Souza et al.
European journal of pharmacology, 403(1-2), 121-128 (2000-09-02)
Reperfusion of ischemic vascular beds may lead to recruitment and activation of leukocytes, release of mediators of the inflammatory process and further injury to the affected vascular bed and to remote sites. Neutrophils appear to play a major role in
M P Fink et al.
Critical care medicine, 21(12), 1825-1837 (1993-12-01)
To evaluate the hypothesis that treatment with LY255283, a novel leukotriene B4-receptor antagonist, is beneficial in an animal model of the adult respiratory distress syndrome induced by endotoxin. Prospective, randomized, controlled trial. Laboratory at a large university medical center. Twenty-five
J S Sawyer et al.
Journal of medicinal chemistry, 38(22), 4411-4432 (1995-10-27)
Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These
Eun-Young Kim et al.
Free radical biology & medicine, 49(6), 1072-1081 (2010-07-06)
Aggressive bladder cancer is a major cause of morbidity and mortality. Despite the fact that metastatic disease results in death in the majority of bladder cancer cases, the molecular events regulating the invasive phenotype of aggressive bladder cancer are not
P S Wollert et al.
Surgery, 114(2), 191-198 (1993-08-01)
Polymorphonuclear neutrophils (PMNs) have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). Because leukotriene B4 (LTB4) is a potent activator of PMNs, we sought to determine whether LY255283, an LTB4 receptor antagonist, could block PMN activation
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| L1920-25MG | 04061833024256 |
| L1920-5MG | 04061833024263 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持